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Highly active anti-retroviral therapy (HAART)
and prophylactic therapy for opportunistic
infectionhavesignificantlyimprovedthesurvival
and quality of life for patients infected with the
Human Immunodeficiency Virus (HIV). 2
Lymphoproliferative disease complicates the
clinicalcourseofHIVinfectioninapproximately
10% of patients and the incidence of Non
Hodgkins Lymphoma is 60-200 times more
common than the general population.3'4 Diffuse
large B cell lymphoma, Burkitt's Lymphoma,
Burkitt like Lymphoma and Primary Cerebral
Lymphoma are the most common subtypes with
Hodgkins Disease, Plasmacytoma and Body
Cavity Based Lymphomas also increased in
incidence.4AcuteBcelllymphoblastic leukaemia
(B ALL) is uncommon representing 5% of all
adult patients with ALL.s An association with
HIV infection is rare and limited to case reports.
We report the case of a 40 year old man and
discuss his treatment and clinical course. We
suggestthat B cell ALL shouldbe included inthe
criteria for a diagnosis of the Acquired
Immunodeficiency Syndrome (AIDS) and that
patients presenting with this type of leukaemia
shouldbefullyassessedregardingriskfactorsfor
HIV infection and when necessary tested
following appropriate counselling. We support
present recommendations thatpatients with HIV
associatedlymphoproliferative diseasereceiving
chemotherapyshouldreceiveconcurrentHAART
and when possible are entered into clinical trials
where the maximal therapy can be addressed.
CASEREPORT A40yearoldhomosexualmale
presented to aDistrictGeneral Hospital inMarch
1999 with a short history of a chest infection,
shortness ofbreath, night sweats, weightloss and
left facial weakness. Physical examination
revealed a complete left lower motor neurone
facial nerve palsy, dullness and crepitations at
the right base and smooth hepatosplenomegaly.
Therewasnoperipherallymphadenopathy sternal
tenderness ortesticularenlargement. Hehadbeen
previously well and working as a fitness
instructor. Six years previously he attended a
genitourinary clinic where he tested positive for
HIV. He declined treatment at this time and was
lost to review.
INVESTIGATIONS
Haemoglobin was 10 g/dl with aplatelet countof
135 x 109/1 and a white cell count of 9.6 x 109/1.
The differential white cell count revealed
lymphocytes at 4.0 x 109/1, neutrophils at 4.5 x
109/1, monocytes at 0.8 x 109/1 and blasts cells of
L3 morphology at 0.2 x 109/1. Lactate
dehydrogenase (LDH) was 10 828 iu/l with a
urate level of 0.58 mmol/l.
Chest radiograph showed a right hilar mass with
anassociatedpleuraleffusion. Subsequentpleural
aspiration revealed the presence of blast cells.
Computerized axial scanning (C.T.) confirmed
the chestfindings andhepatosplenomegaly. C.T.
scan of the brain was normal however
Cerebrospinal fluid (CSF) examination revealed
L3blastcells. Bonemarrowaspirateandtrephine
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biopsy revealed apacked marrow withblastcells
exhibiting characteristic L3 morphology with
basophilic cytoplasm and vacuolation. (Figure).
Immunophenotype of these blast cells revealed
strongpositivity forthe B cell markers CD19 and
CD22withweakerexpressionofCD10. Terminal
deoxynucleotidyltransferase(TDT)wasnegative.
This immunophenptype in combination with the
morphological findings was in keeping with a
diagnosis of Acute B cell Lymphoblastic
Leukaemia. Virology confirmed HIV positivity
with a viral load of 1.3 x 106 copies per/ml.
Fig. Bone marrow aspirate showing blast cells of L3
morphologyexhibitingbasophilic andvacuolated
cytoplasm. (Wrights Stain)
Hepatitis A B C, Epstein Barr Virus and
Cytomegalovirus all tested negative and the
CD4+ve lymphocyte count was 475 /l. Due to
biohazard regulations within the Cytogenetics
Laboratorywewereunabletoobtainacytogenetic
result.
TREATMENT
He received combination chemotherapy with the
COP/COPADM/mini CYVE regimen. This
containing combinations of the drugs
cyclophosphamide, vincristine, prednisolone,
doxorubicin,ARA-C,etoposideandmethotrexate.
High dose methotrexate was administered at a
dose of 8 gm/M.2 Intrathecal chemotherapy was
given and followed by cranial irradiation.
He declined anti-retroviral therapy initially
however following discussion this was
commenced in August 1999 with zidovudine,
lamivudine and efavirenz. Repeat viral load was
<150copies/mlinDecember 1999. Chemotherapy
waswelltoleratedwithnoopportunisticinfections
and interestingly a period of prolonged
thrombocytopenia responded to commencement
of the anti-retroviral therapy. Co-trimoxazole
and fluconazole prophylaxis were administered.
Haematological remission was achieved in his
blood and bone marrow with resolution of the
chest x ray appearances. Despite the absence of
blasts in his CSF there was no resolution of his
facialnervepalsy. Hehad2HLAmatchedsiblings
andwasconsideredforallogeneictransplantation
however his remission was short lived and he
relapsed 2months laterwithinhis chest, CSFand
bone marrow with an LDH measuring 40 000p1l.
Despite further attempts at re-induction he was
unable to achieve a complete second remission
and died in February 2000.
DISCUSSION
Highly active anti-retroviral therapy (HAART)
and prophylactic therapy against opportunistic
infection have significantly decreased the
morbidity and mortality associated with the
Human Immunodeficiency Virus (HIV).1'2
Lymphoproliferative disease complicates the
clinical courseinapproximately 10% ofpatients.
This incidence may be decreasing since the
introduction ofHAART as suggested in a recent
meta-analysis and appears most marked for
Primary Cerebral Lymphoma.3 The
pathogenesis is not completely understood
however continued B cell proliferation in the
absence ofnormal T cell immunosurveillance is
a likely factor with the Epstein Barr Virus
implicated in many cases.3'4 Rarely HIV may be
directly oncogenic in T cell lymphomas and
Human Herpes Simplex Virus 8 (HHV 8) has
been implicated in Body Cavity Based
Lymphoma.4Treatment is difficult as the disease
is often advanced at diagnosis with extranodal
and bone marrow involvement present. The risk
of opportunistic infection is increased with
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intensive chemotherapy and viral induced
myelodysplasia may delay recovery of bone
marrow function.3 There is also a concern that
chemotherapy may exacerbate HIV infection.
Adverse prognostic features are a poor
performance status, a prior diagnosis of AIDS
(AcquiredImmune Deficiency Syndrome), CD 4
lymphocyte count <100 p/1 and extranodal
disease, particularly central nervous system
involvement. The overall survival is usually less
than 1 year.6 Several chemotherapy regimens
have been investigated and an initial randomised
trial comparing a low dose and standard dose
chemotherapy regime (mBACOD) with
granulocyte - macrophage colony stimulating
factor(GIVI-CSF) support showedno difference
inresponse orsurvivalinthetwogroupshowever
there was an increase in the incidence of
neutropenic sepsis inthefull dosearm.7 Recently
developed protocols have resulted in improved
response and survival rates, particularly in good
risk patients. There is also the suggestion of
improved survival since the introduction of
HAARTin 1996 withfurther studies requiredfor
confirmation.8' 9
Acute B cell lymphoblastic leukaemia (B ALL)
is characteristically associated with central
nervous systeminvolvementandapoorprognosis.
The cytogenetic abnormality t(8:14) is present in
themajorityofcasesthisresultingindysregulation
ofthec-myc proto-oncogene which is implicated
in pathogenesis. Morphology is characteristic
with blast cells exhibiting strongly basophilic
cytoplasm and vacuolation (Figure). Recent
intensive protocols incorporating high dose
methotrexate and ARA-C have shown improved
survival rates in both children and adults.'0
B ALLinassociationwithHIVisrareandlimited
to case reports. Approximately 22 cases have
been reported to date."I In most previously
reported cases there was no history ofAIDS and
the CD 4 count was reasonably well preserved at
diagnosis."I This pattern of presentation was
similar in our patient. Treatment with intensive
combination chemotherapy was well tolerated
and no atypical opportunistic infections were
encountered. An episode of prolonged
thrombocytopenia of less than 20 x 109/1 for 5
months responded to the initiation of anti-
retroviral therapy with counts improving to 70 x
109/1 and was suggestive of viral induced
thrombocytopenia. Prior to relapse this patient
had been considered for an allogeneic bone
marrow transplant, syngeneic transplantation
having previously been described in an HIV
positive haemophiliac patient with ALL.'2 The
poor survival of our patient was similar to the
majority of cases reported.
The impact ofHAART on survival remains to be
seen and although overlapping toxicities and
interactions may occur it is recommended all
patients receive this therapy in combination with
chemotherapy. Although more evidence is
awaiteditispossiblethathadourpatientreceived
anti-retroviral therapy earlier in the course ofhis
infection this may have delayed or prevented the
onset of his B ALL. The recent success of
monoclonal antibodies, immune modulation and
stemcell transplant regimens are likely to extend
toHIVassociatedlymphoma/leukaemia andoffer
promising therapies in the future.'3 Present
optimalmanagementrequires amultidisciplinary
approach with specialist Haematologists/
Oncologists in liason with expert physicians in
treating HIV infection.
Werecommendthatpatients shouldbetreatedon
an individual basis and those whose immune
system is less compromised with a good
performance status are candidates for intensive
therapy. We suggest that a statement indicating
thatBALLandBurkitt'sLymphomaaredifferent
clinicalmanifestationsofthesamediseaseprocess
should be included in the Centres for Disease
control (CDC) criteriafordiagnosis ofAIDS and
recommend that all patients with B ALL should
be assessed regarding risk factors for HIV and if
appropriate tested following counselling. As we
are likely to encounter more of these patients in
the future entrance to clinical trials should be
encouraged to improve the overall outcome.
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